Print Page | Close Page

---

Teva Pharmaceuticals

Address: Petach Tikva, 49131 Country: Israel Sectors: Proprietary Research & Manufacture, Generic Formulations, Contract Manufacturing Telephone: +972-3-9267267 Fax: +972-3-9234050 Website: http://www.tevapharm.com - - -

About Us

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva currently employs approximately 46,000 globally and reached $18.3 billion in net revenues in 2011.

- - -

Sectors

- - -

Categories

- - -

Certifications

- - -

News

11th January 2018

Wondering how Teva found room to cut $3B? Look at its past mistakes, CEO says

SAN FRANCISCO—Since new CEO Kåre Schultz rolled out Teva’s $3 billion cost-cutting plan a few weeks back, “some have asked me, ‘how on earth is this possible?’” he said Monday at the J.P. Morgan Healthcare Conference. - 18th December 2017

Generic drugs giant Teva to cut workforce by more than 25%

No decision on future of Irish plants which employ about 580 - 12th December 2017

Teva shares up on report of 10,000 job cuts

Generic pharma company employs some 500 in Ireland - 26th September 2017

Teva betting on Schultz as CEO with $40m package

Dane lands top job with beleaguered generics giant after reviving Lundbeck’s fortunes - 16th February 2017

Teva sees higher active pharmaceutical ingredient sales in 2016

Copaxone maker Teva Pharmaceutical Industries Ltd. saw higher active pharmaceutical ingredient (API) sales last year.

in-2016 - 13th January 2017

Drug firm Teva predicts 2017 revenue and profit below estimates

Israel company expects earnings per share of $4.90-$5.30 on revenue of $23.8bn-$24.5bn - 05th August 2016

Teva Reports First Quarter 2016 Results

Teva Reports Second Quarter 2016 Results
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the quarter ended June 30, 2016. - 03rd August 2016

Teva completes acquisition of Allergan’s generic’s business

Deal was announced a year ago and came with $40.5bn price tag - 31st March 2016

Takeda and Teva Establish “Teva Takeda Yakuhin Ltd.” in Japan

Takeda and Teva Establish “Teva Takeda Yakuhin Ltd.” in Japan - 27th July 2015

Israel's Teva to buy Allergan for $40.5bn

Israeli pharmaceutical giant Teva said that it was buying the generic drug business of Allergan for $40.5 billion, consolidating its position as a world leader in generics. - 22nd April 2015

Unsolicited Takeover Bid for Mylan

Teva, the world’s biggest maker of generic medicines, offered $82 a share in cash and stock, according to a statement. That’s about 23 percent above Mylan’s closing price April 16, the day before Bloomberg News reported Teva was considering a bid. Mylan, which says it makes about one of every 11 drugs prescribed to Americans, has said it wants to stay independent and that a combination with Teva would face antitrust hurdles. - 31st March 2015

Teva to buy U.S. drug developer Auspex Pharma for $3.5 billion

Israel's Teva Pharmaceutical Industries said it would buy U.S. neurology drug company Auspex Pharmaceuticals Inc for an equity value of $3.5 billion to boost its portfolio of treatments for the central nervous system. - - - Printed: 16-Apr-2026 at 12:13:31 hrs
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com